Supernus Pharmaceuticals (SUPN) Earns Buy Rating from B. Riley

Share

The posibility that the deal remains unnoticed are super little due to the huge amount of money involved. Frontier Cap Limited Liability Company invested in 0.78% or 1.79M shares. The company's shares were unloaded on January 17, 2018 and the Form 4 that contains the original information, filed with the U.S. Security and Exchange Commission can be accessed here. Bruce & Co Inc who had been investing in Supernus for a number of months, seems to be bullish on the $2.40 billion market cap company. It operates through Public Service Company of New Mexico and Texas-New Mexico Power Company (TNMP) divisions. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, January 12th. Therefore 70% are positive.

Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) presently has a current ratio of 1.82. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. Cantor Fitzgerald restated a "buy" rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. The company was maintained on Tuesday, September 19 by Cowen & Co.

Analysts await Supernus Pharmaceuticals, Inc. The company's revenue for the quarter was up 41.5% on a year-over-year basis. sell-side analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current year. (NASDAQ:SUPN) earned "Outperform" rating by Northland Capital on Thursday, November 5. (NASDAQ:SUPN) earned "Buy" rating by Stifel Nicolaus on Monday, July 17. Jefferies maintained Supernus Pharmaceuticals, Inc. The rating was maintained by Cowen & Co on Tuesday, September 19 with "Buy". (NYSE:VZ), 6 have Buy rating, 0 Sell and 20 Hold. The firm has "Overweight" rating by PiperJaffray given on Thursday, June 1. The rating was initiated by SunTrust on Monday, January 25 with "Buy". As per Thursday, August 4, the company rating was maintained by Jefferies.

Ny State Teachers Retirement Systems invested 0.01% of its portfolio in Supernus Pharmaceuticals, Inc. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It has a 41.86 P/E ratio. The company??s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. The company had a trading volume of 349,279 shares.

Supernus Pharmaceuticals (SUPN) traded up $3.35 on Thursday, hitting $46.90. It has outperformed by 75.10% the S&P500.

Klopp states he would never sell to a rival mid-season
Swansea have only scored six of their 27 goals across 13 Premier League games against Liverpool at the Liberty Stadium . Virgil van Dijk should be available after missing last weekend's win over Manchester City with a tight hamstring.

NasdaqGM:SUPN is 0.036504. Earnings Yield helps investors measure the return on investment for a given company. Narrowing in a bit closer, the 5 month price index is 0.99090, the 3 month is 1.02230, and the 1 month is now 1.14605. It turned negative, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. Numeric Investors Limited Liability Company invested 0.02% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). State Common Retirement Fund accumulated 0.01% or 258,676 shares. Gamco Et Al stated it has 587,550 shares. Karp Capital Management holds 2,833 shares. Riverhead Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. NasdaqGM:SUPN is 0.025956. This is calculated by taking the earnings per share and dividing it by the last closing share price. The data from the past twelve months tells a similar story: insiders executed 2 buys and 21 sells, and ownership decreased by a net of 414306 shares. Macquarie Gp Ltd holds 0.01% or 87,188 shares in its portfolio. Vident Inv Advisory Ltd Liability Co reported 31,747 shares or 0.09% of all its holdings. Winslow Evans And Crocker Inc invested 0.09% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Alpha Cubed Invs owns 0.04% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 1.48M shares. Moreover, Boston Prtn has 0.14% invested in United Continental Holdings, Inc. (NASDAQ:SUPN) or 29,400 shares. Glg Limited reported 27,754 shares. After $0.98 actual earnings per share reported by Verizon Communications Inc. for the previous quarter, Wall Street now forecasts -10.20% negative EPS growth.

Since August 16, 2017, it had 0 buys, and 10 insider sales for $14.52 million activity. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02.

Since August 28, 2017, it had 0 insider purchases, and 3 sales for $89,365 activity. (NASDAQ:SUPN) shares. PATRICK GREGORY S sold 50,000 shares worth $2.18 million. Schwabe Stefan K.F. sold $4.43 million worth of stock.

Ratings analysis reveals 67% of PNM Resources's analysts are positive. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. PNM was included in 3 notes of analysts from September 20, 2016. A low number in the 1-2 range typically indicates a Buy, 3 indicates a Hold and 4-5 represents a consensus Sell rating. On Tuesday, January 2 the stock rating was maintained by Stifel Nicolaus with "Buy". 51,000 were reported by Bridgeway Capital Management Inc. The stock increased 0.42% or $0.04 during the last trading session, reaching $9.5. That activity is comparable to their recent volume average trend of almost 1.65 million shares which they recorded over a period of three months. CNX Resources Corporation (NYSE:CNX) has risen 22.10% since January 18, 2017 and is uptrending.

(NasdaqGM:SUPN) is 1.82. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. (NYSE:VZ) to report earnings on January, 23. PNM's profit will be $20.71 million for 34.76 P/E if the $0.26 EPS becomes a reality. 387.06 million shares or 0.01% more from 387.02 million shares in 2017Q2 were reported. Calamos Wealth Management Ltd Limited Liability Company invested in 1,634 shares. Moreover, Mesirow Financial Investment Management has 0.75% invested in the company for 280,911 shares. (NASDAQ:SUPN). United Fincl Advisers Llc, a California-based fund reported 47,052 shares.

Share